Results 121 to 130 of about 7,117 (221)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. [PDF]

, 2021
Calvo, R, De Vos, S, Dyer, MJS, Flowers, CR, Frigault, MM, Maddocks, KJ, Patel, P, Ruan, J, Rule, S, Strati, P, Wei, H, Xu, Y   +11 more
core   +2 more sources

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. [PDF]

Biomolecules
Duminuco A, De Luca P, Stanzione G, Caruso LA, Lavenia G, Scarso S, Garibaldi B, Palumbo FE, Vetro C, Palumbo GA.   +9 more
europepmc   +1 more source

Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. [PDF]

J Manag Care Spec Pharm
Fitzgerald L, Ghosh S, Khan W, Bokun A, Lax A, Mu F, Cook EE, Chen J, Chen G, Wu E, Lin Y, Shi L, Qureshi ZP, Graf SA.   +13 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter's syndrome. [PDF]

Leuk Res Rep
Meier T, Huynh G, Ayala E, Tun HW, Iqbal M.   +4 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Leukemic penile ulcer as the presenting symptom of chronic lymphatic leukemia. [PDF]

J Surg Case Rep
Sandhu HS, Chandra S, Joshi S.
europepmc   +1 more source

Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. [PDF]

Future Oncol
Dingli D, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt H, Zhang X, Lodaya K, Obeng-Kusi M.   +10 more
europepmc   +1 more source

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

, 2018
Bartlett, Nancy L.
core   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. [PDF]

Front Pharmacol
Zhang Y, Fu H, Kang X, Qiu Z, Yan H, He Q, Yang B, Xu Z, Luo P.   +8 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source